Literature DB >> 28399389

Anthelmintic Flubendazole and Its Potential Use in Anticancer Therapy.

Kristýna Čáňová1, Lucie Rozkydalová2, Emil Rudolf3.   

Abstract

Flubendazole is a widely used anthelmintic drug belonging to benzimidazole group. The molecular mechanism of action of flubendazole is based on its specific binding to tubulin, which results in disruption of microtubule structure and function, and in the interference with the microtubule-mediated transport of secretory vesicles in absorptive tissues of helminths. The microtubule-disrupting properties of benzimidazole derivatives raised recently interest in these compounds as possible anti-cancer agents. In this minireview flubendazole effects towards selected human malignant cells including myeloma, leukemia, neuroblastoma, breast cancer, colorectal cancer and melanoma are discussed along with basic data on its pharmacokinetics, metabolism and toxicity.

Entities:  

Keywords:  anti-cancer treatment; benzimidazole carbamate; flubendazole; melanoma; microtubules; mitotic catastrophe

Mesh:

Substances:

Year:  2017        PMID: 28399389     DOI: 10.14712/18059694.2017.44

Source DB:  PubMed          Journal:  Acta Medica (Hradec Kralove)        ISSN: 1211-4286


  13 in total

1.  Biological Evaluation of a Potential Anticancer Agent Methyl N-[5-(3'-Iodobenzoyl)-1H-Benzimidazol-2-yl]Carbamate.

Authors:  Zbigniew P Kortylewicz; Don W Coulter; Janina Baranowska-Kortylewicz
Journal:  Cancer Biother Radiopharm       Date:  2019-11-05       Impact factor: 3.099

2.  Repositioning Flubendazole for Spinal Cord Injury.

Authors:  Chen Guang Yu; Vimala Bondada; Sarbani Ghoshal; Ranjana Singh; Christina K Pistilli; Kavi Dayaram; Hina Iqbal; Madison Sands; Kate L Davis; Subarrao Bondada; James W Geddes
Journal:  J Neurotrauma       Date:  2019-03-15       Impact factor: 5.269

3.  Flubendazole inhibits glioma proliferation by G2/M cell cycle arrest and pro-apoptosis.

Authors:  Xumin Zhou; Jumei Liu; Jinming Zhang; Yong Wei; Hua Li
Journal:  Cell Death Discov       Date:  2018-02-14

4.  [Flubendazole Inhibits the Proliferation of A549 and H460 Cells and Promotes Autophagy].

Authors:  Tingjun Dong; Zejun Lu; Jingjiao Li; Yongzhen Liu; Juyi Wen
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2020-05-20

5.  Inhibiting eukaryotic ribosome biogenesis.

Authors:  Dominik Awad; Michael Prattes; Lisa Kofler; Ingrid Rössler; Mathias Loibl; Melanie Pertl; Gertrude Zisser; Heimo Wolinski; Brigitte Pertschy; Helmut Bergler
Journal:  BMC Biol       Date:  2019-06-10       Impact factor: 7.431

6.  Combination Anthelmintic/Antioxidant Activity Against Schistosoma Mansoni.

Authors:  Maria João Gouveia; Paul J Brindley; Gabriel Rinaldi; Fátima Gärtner; José Manuel Correia da Costa; Nuno Vale
Journal:  Biomolecules       Date:  2019-02-05

7.  The Influence of Chestnut Wood and Flubendazole on Morphology of Small Intestine and Lymphocytes of Peripheral Blood, Spleen and Jejunum in Broiler Chickens.

Authors:  M Levkut; V Revajová; M Levkutová; E Selecká; Z Ševčíková; V Karaffová; M Levkut
Journal:  Helminthologia       Date:  2019-10-30       Impact factor: 1.184

Review 8.  Repurposing of Drug Candidates for Treatment of Skin Cancer.

Authors:  Hernán Cortés; Octavio D Reyes-Hernández; Sergio Alcalá-Alcalá; Sergio A Bernal-Chávez; Isaac H Caballero-Florán; Maykel González-Torres; Javad Sharifi-Rad; Manuel González-Del Carmen; Gabriela Figueroa-González; Gerardo Leyva-Gómez
Journal:  Front Oncol       Date:  2021-01-08       Impact factor: 6.244

9.  The anthelmintic drug flubendazole induces cell apoptosis and inhibits NF-κB signaling in esophageal squamous cell carcinoma.

Authors:  Jiali Tao; Hongmei Zhao; Xiaochen Xie; Man Luo; Zhiwei Gao; Hong Sun; Ziming Huang
Journal:  Onco Targets Ther       Date:  2019-01-09       Impact factor: 4.147

Review 10.  The Antitumor Potentials of Benzimidazole Anthelmintics as Repurposing Drugs.

Authors:  Deok-Soo Son; Eun-Sook Lee; Samuel E Adunyah
Journal:  Immune Netw       Date:  2020-08-04       Impact factor: 6.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.